The concentrations of laminin, a high molecular weight non-collagenous glycoprotein of basement membranes, and of the N-terminal propeptide of type III procollagen were determined in the senim of the liver outflow vascular region (hepatic vein) and of a peripheral vein (cubital vein) in patients with chronic liver diseases (fibrosis, cirrhosis, unspecified histology; n = 173), in order to determine their secretion rates from the injured livers. The mean levels of laminin (1.84 kU/1) and of procollagen peptide (28.0 g/l) in hepatic vein were significantly higher (about 9.5% at p < 0.02, and 37% at p < 0.001, respectively) than those in the periphery (1.68 kU/1 and 20.4 g/l, respectively). In chronic liver diseases, however, laminin and procollagen peptide concentrations in the hepatic vein were lower than or equal to those in the cubital vein in 18% and 27% of patients, respectively. The highest regional differences of the concentrations were noted in cirrhotic sübjects. The seruin levels of laminin (r s 0.93) and of procollagen peptide (r s 0.73) in hepatic and in cubital vein are highly positively correlated (p < 0.001), but the levels of procollagen peptide in hepatic vein are only weakly but still significantly statistically related with those of laminin (r s 0.446, p < 0.001). Similarly, the hepatic-cubital venous concentration differences of both proteins are weakly (r s 0.312) but significantly (p < 0.001) correlated. On the basis of several assumptions we estimated secretion rates from the livers of 120 U · min" 1 för laminin, and 5.7 g · min" 1 for procollagen peptide. These data support the view that the chronically injured human liver is highly active in producing serum laminin and procollagen peptide, which are measured in elevated concentrations in the senim of liver fibrotic and cirrhotic sübjects.
is accomplished by a stimulated production in various Fibrosis, a inain histological featüre of liver eirrhosis, parenchymal and non-parenchymal types of liver is characterized biochemically by several fold in-cells, but the mechanisms of enhanced synthesis are creases of the ainounts and changes of the molecular only pporly understood (2) . Along with the developcomposition of various types of eollagens ( , III, ment of liver fibrosis, the concentrations of some IV, V, VI), noncollagenous (structural) glycoproteins connective tissue-derived proteins or their cleavage (fibrpnectin, laminin), proteoglycans (heparan sul-products increase in serum, an observation which has phate, chondroitiü sulphate, dennatan sulphate), and been exploited for clinical chemical diagnosis and glycosaminoglycans (hyaluronic acid) iti the extracel-follow-up of fibrogenesis (3, 4) . Among these paralular space of the liver tissue (1) . Their accumulation .meters, the determination of the concentration of the aininoterminal propeptide of type III procollagen has found wide clinical application in the monitoring of patients with chronic liver diseases, who risk development of fibrosis and cirrhosis (3) (4) (5) (6) . The level of procollagen peptide in serum has been shown to be closely correlated with the activity of the fibrogenic process (7 -14) and the extent of the fibrotic transformation (7, (15) (16) (17) of chronically injured liver. Recently, elevated concentrations of Iaminin, a high molecular weight (M r ~ l · l O 6 ) noncollagenous glycoprotein constituent of basement membranes (18, 19) , have been measured in the sera of fibrotic and cirrhotic liver patients; the extent of the elevation was reported to be correlated with the severity of organ fibrosis (17, 20 -24) and the degree of portal hypertension (21 -24) . The mechanism of the elevation of the connective tissue proteins in serum of fibrotic liver patients is not clear. It may be due to enhanced synthesis and fractional secretion by the producing cell types of the liver, stimulated break-down and discharge into the circulation of intercellularly deposited matrix proteins, or by reduced clearance of circulating connective tissue proteins originating from nonhepatic sources. In the following study we attempted to define the production of serum procollagen peptide and Iaminin in fibrotic livers by measuring their concentrations selectively in the liver outflow and comparing them with the respective levels in peripheral venous regions. Based on several assumptions, we tried to estimate the order of magnitude of the contribution of fibrotic livers to the serum pool of Iaminin and procollagen peptide, respectively.
Materials and Methods

Patients
Hospitalized patients with chronic liver diseases (n = 173) of various aetiologies (50% chronic alcohol consumption, 22% posthepatitis B, 28% miscellaneous and unknown) were subdivided into those with histologically verified fibrosis (n = 55) and cirrhosis (n = 41), and those (n = 77) with unspecified histology where a liver biopsy specimen was not available. The hepatic vein of all patients was catheterized for measurement of portal vein pressure (25) . Patients were informed äbout the procedure and gave their consent. Venous catheterization was performed with a Swan-Ganz balloon catheter starting froin the right femoral vein using Seldinger's technique (26) . The tip of the catheter was introduced into the right hepatic vein under fluoroscopic control.
Specimen collection
Blood was aspirated simultaneously from the hepatic vein and from the periphery (cubital vein). All patients were in an overnight fasting state. After allowing the blood to clot for l h at room temperature serum was prepared by centrifugation and stored at -70 °C for a maximum of one month before the assays were performed.
Assay of N-terminal propeptide of type III procollagen
The propeptide was analysed in various dilutions (1:5, l :20, l: 50) of serum by a radioimmunoassay for the aminotenninal propeptide of type III procollagen (Behring-Hoechst, Frankfurt, FRG). Details of the assay have been described previously (27) (28) (29) . The within-run coefficient of Variation (CV) was 4.9% (x = 12 ^; n = 40); the day-to-day CV was 7.2% (x = 5.0 g/l; n = 36). The upper limit'of the reference ränge of procollagen peptide in serum is ^ 12 g/l (29) .
Assay of Iaminin
The concentration of the glycoprotein was determiiied with a competitive radioimmunoassay (Behring-Hoechst, Frankfurt, FRG), details of which are reported elsewhere (30) . The änti-body is directed against antigenic determinants of the pepsinr esistant fragment Pl of Iaminin (31) . The coefficients of Variation of the within-mn and day-to-däy imprecisions were 3.1% and 4.9% (x = 2.0 kU/1), respectively. The inaccuracy ranged from -12% to + 11%. During storage at -20 °C no significant loss of Iaminin was npted. According to the mänufacturer of the test reagents, the concentrations of Iaminin are gjven in arbitrary kU/1 because an international Standard of Iaminin is not available; l U is deflned äs the mean quantity of Iaminin per ml serum in a group of obviously healthy persons and corresponds to about 0.230 g (31) . The reference ränge of Iaminin in serum (2.5 -97.5 percentile) was detennined previously to be 0.81-1.43 kU/1 (median 1.04 kU/1) (21).
Estimation of liver production rates of Iaminin and propeptide of type III procoljagen Synthesis and/or secretion rates of the respective connective tissue proteins in the liver were calculated from the difference between the antigen concentrations in the liver outflow vascular region (vena hepatica) and in a peripheral vein (veiaa cubitalis), based on the following assumptions: i) a blood perfusion rate of the liver of 1.50 l/min per 1.73 m 2 body surface area (32) , ii) liver inflow concentrations of the proteins corresponding to those ineasured in the cubital vein, iii) identical concentrations of the respective proteins in portal vein (providing 70 to 75% of total liver blood supply) and hepatic artery (25 to 30% of blood supply), iv) a mean haematocrit of 0.50 (33) , and v) a plasma volume of 0.025 to 0.045 l/kg body weight (34) corresponding to a total body (70 kg) plasma volume of about 2.51.
Statistical methods
Differences between groups were tested with the Mann-Whitney-Wilcoxon U-test; p < 0.05 was considered to be stätisticaily signiflcant. Correlations are described with Spearmari's rank correlation coefficient (fs) (35) .
Results
Concentrations of Iaminin and procollagen peptide in hepatic vein and cubital vein of patients with chronic liver diseases
The mean serum Iaminin concentrations in hepatic (1.84 kU/1) and cubital (1.68 kU/1) vein of all patients with chronic liver diseases % were significantly (p »; j. Clin. Chem. Clin. BiöGhem. / Vol. 25,1987 / No. 9 < 0.001) elevated if compared with the reference concentration of the glycoprotein in cubital vein (0.81-1.43 kU/1) (tab. 1). In both vascular regions the concentrations of laminin were found to be higher in cirrhotic subjects than in patients with mere liver fibrosis (tab. 1). Qualitatively similar results were obtained for the procollagen peptide; the mean concentrations of this peptide in hepatic and cubital vein of cirrhotic patients were higher than those measured in liver fibrotic individuals (tab. 2). The mean procollagen peptide concentrations in hepatic (28.0 §/1) and in cubital (20.4 g/l) vein of the total population of patients were greatly elevated compared with the reference ränge (2-12 g/l) of the procollagen fragment in serum.
There was a significant correlation (p < 0.001) between the concentrations of the respective proteins in hepatic vein and cubital vein, but the correlation for procollagen peptide (r s 0.734) was lower than that for laminin (r s 0.93) (figs. l, 2). A weak (r s 0.446) but still significant statistical relation (p < 0.001) was observed between the concentrations of laminin and procollagen peptide in hepatic vein (Fig. 3 ).
In the majority of patients with chronic liver diseases the concentrations of laminin and procollagen peptide were found to be higher in the hepatic vein than in the peripheral vascuiar region (tab. 3). Fractions of only 0.18 and 0.27 of all patients with chronic liver diseases had concentrations of laminin and procollagen peptide, respectively, in the hepatic vein which were equal to or lower than those in the cubital vein (tab. 3). The fractions of positive and negative hepatic-cubital venous concentration differences of both matrix proteins varied slightly between the different groups of liver diseases (tab. 3). The frequency distribution of the quantitative differences of the laminin and procollagen peptide concentrations, respectively, between hepatic and cubital vein is shown in figure 4 . It is demonstrated that about half of the patients had eoncentrations of laminin in the hepatic vein, which were 10 to 20% higher than those in the cubital vein. Larger regional concentration differences were observed more frequently for procollagen peptide than for laminin, but negative concentration differences f laminin occurred less frequently than those of procollagen peptide ( fig. 4 ). The hepatic-cubital venous concentration differences of laminin and procollagen peptide in cirrhotic patients were higher than those found in liver fibrotic subjects (tabs. l, 2). In fibrotic patients, the concentration differences of both proteins were statistically non-significant; the same was true for laminin in liver cirrhotic subjects. In all patients with chronic liver diseases the mean concentration differences of laminin and of procollagen peptide were found to be 0.16 kU/1 (p < 0.02) and 7.6 μg/l (p < 0.001), respectively, but a large statistical Variation was noted. The largest regional concentration differences observed for laminin and procollagen peptide were l .59 kU/1 and 37.4 μΐ*/1, respectively, both being measured in liver cirrhotic patients. There was a weak but significant correlation between the hepatic-cubital venous concentration differences of procollagen peptide and laminin (r s 0.312, p < 0.001). The regional concentration differences were not correlated with the aetiology of the chronic liver disease, the portal venous pressure, or the stages of oesophageal varices; there was also no correlation with a number of routine clinicalchemical liver parameters (aspartate and alanine aminotransferases, γ-glutamyl-transferase, bilirubin) (data not shown).
Estimation of the production rates of serum laminin and procollagen peptide in fibrotic and cirrhotic livers Based on the above described assumptions, the net production (synthesis and/or secretion) rates of 120U -min" 1 for laminin and 5.7 μg -min" 1 for procollagen peptide were calculated for the total pop lation of patient$ with chronic liver diseases. These values were slightly higher in cirrhotic and lower in liver fibrotic subjects (tabs. l, 2). The chronically injured liver would therefpre be able to produce the 4200 U of laminin present in the total body plasma volume of 2.51 (calculated fr m the mean concentration in the cubital vein) in about 35 min; this time would be longer for fibrotic (79 min) and shorter for cirrhotic livers (29 min). Similarly, the total plasma pool of procollagen peptide of 51 μg would be f eplenished by the chronically injured liver in ab ut 9 min; a slightiy longer time (l l min) would be requjred by fibrotie and a shorter time (6.4 min) by cirrhotic livers.
Discussion
It is well established by quantitative biochemical data and iinmunofluorescence (-peroxidase) staining methods that in chronically injured liver an excessive intercellular depesition of collagens (36) (37) (38) (39) (40) (41) (42) and of laminin (43, 44) occurs. Type III collagen is distributed uniformly within the lobulus and is present in the space of Disse and around the central vein (45) . Laminin, which is a main constituent of all basement membranes (18, 19) , is normally (almost) absent from the Disse space (43, 46) . In alcoholic liver injury, however, laminin appears in the Disse space, where it can be intensely stained by immunologic methods, together with the light and electron microscopic appearance of basement membranes beneath the endothelial cell layer of the sinusoid (43, 44, 47) . The accumulation of the matrix proteins in fibrotic liver is brought about by their stimulated synthesis and secretion in some sinusoidal types of liver cells (e. g. fat-storing cells, endothelial cells) (48) but recent findings point to parenchymal liver cells (hepatocytes) s additional sources of collagen production in the liver (42, 49 -57) . It is conceivable that during the process of intercellular deposition of newly formed laminin and procollagen peptide, fractions of the respective proteins escape into the circulation, thereby contributing to elevated concentrations in the liver outflow. In accordance with this hypothesis it is shown in the present study that the mean concentrations of laminin and procollagen peptide in the serum of the liver outflow vascular region are respectively 9.5% and 37.2%, higher than those in a peripheral vein. Similar regional differences in the concentrations of these proteins were also observed in a preliminary study with a limited number of patients (23) . Assuming liver inflow concentrations (similar in portal vein and hepatic artery) of laminin and procollagen peptide identical with those measured in the systemic circulation, we conclude from these data that the fibrosing liver secretes a significant fraction of serum laminin and procollagen peptide. It cannot be decided whether this secretion is due t a fraction of newly synthesized matrix proteins escaping into the blood stream before deposition in the lobulus or to discharge of matrix protein (fragments) during breakdown of hepatic connective tissue and tissue remodeling. The latter possibility might be not a remote alternative since it was shown that type III procollagen can be deposited extracellularly without prior cleavage of the aminoterminal extension peptide (58 -60). Thus, elevation of the procollagen peptide in serum, although mainly a split product of the maturation pathway of collagen (61) does not necessarily reflect increased de novo synthesis of this type of collagen, but may originale from the degradation of tissue procollagen present in extracellular fibrils (62, 63). The heterogeneity of aminoterminal propeptide-related antigens in human serum might be accomplished by the different origins and pathways of the propeptide (62-64). The weak correlations between the concentrations and concentration differences of Iaminin and procollagen peptide indicate that the above described mechanisms of their relative elevations in the hepatic vein are likely to be different. On the basis of our assumptions, the data do not point to an impairment of clearance functions of the fibrotic liver äs a cause of raised matrix protein levels in serum; if this were the case, a relative decrease of the respective concentrations in hepatic vein would be anticipated. The latter mechanism was held responsible for the significant elevation of the hyaluronate concentration in the serum of cirrhotic and fibrotic liver patients (65, 66). In fact, the concentrations of hyaluronate in hepatic vein were found to be significantly lower than those in other vascular beds in man, which allowed the calculation of a net hepato-splanchnic clearance of this connective tissue compound of 0.250 l/min (67). Elucidation of the role of the liver in the clearance of Iaminin and procollagen peptide would require the determination of their concentrations selectively in the hepatic artery and portal vein; for obvious reasons this would present insurmountable difficulties.
Calculation of the production rates of the serum fractions of Iaminin and procollagen peptide in human fibrotic liver from the present data must be preliminary. The results may, in fact, be erroneous, because the actual liver inflow concentrations of both proteins cannot be measured, the levels of procollagen peptide and Iaminin in the portal vein (which contributes about 75% of total hepatic blood flow) and the hepatic artery (which provides the remaining 25% (68)) could be different, and the blood perfusion rates of normal liver (32) applied here might be not valid for fibrotic livers. Keeping in mind these serious limitations, the estiinates of relatively high production rates would imply a rather active turnover of the matrix proteins in the circulation, which Supports results of a previous report suggesting a fast catabolism of circulating aminopropeptide even in healthy humans (69). The half-lives of circulating Iaminin and procollagen peptide deduced from our data are in the same order of magnitude äs those of hyaluronate, which were estimated to be 5.8 min (67) ahd 2.7 min (70) in non-liver diseased persons and about 28 min in patients with primary biliary cirrhösis (70). Interestingly, the production rates of both Iaminin and procollagen peptide were found to be higher in cirrhotic subjects than in patients with mere liver fibrosis, an pbservation, which might have a iiumber of äs yet speculative pathobiochemical explanations. Because it is unlikely that the liver is the only source of Iaminin and procollagen peptide in seruxn, the catabolic and/or elimination rates of these proteins could be even higher than those deduced from our data. Presently, the mechanisms and organs participating in the elimination of circulating procollagen peptide and Iaminin are not known. A low mölecular weight fraction of procollagen peptide is eliminated with the ürine (69, 71) but Iaminin (M r ~ l · 1 6 ) and its pepsin-resistant fragment Pl (M T 0.25 -0.44 · l O 6 ) (72), which might occur in the blood stream (20, 21) , do not pass the glomerülar membrane. As mentioned above a clearance function of the liver for both proteins cannot be strictly rüled out by our data because their iminediate liver proximal concentrations are not known. Although the present study Supports the view of the fibrotic liver äs the active producing organ of a significant fraction of serum Iaminin and procollagen peptide, it is obvious that more detailed Information is needed before definite conelusions can be drawn on its role in the händling of circulating matrix proteins.
